Adam H. Ross
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Adam H. Ross has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
A D Dick
1 shared publicationAjay Kotagiri
South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK
1 shared publicationC. Clare Bailey
1 shared publicationC. Collins
Department of Pathology, University Hospitals Bristol Foundation Trust, Bristol, UK
1 shared publicationC. T. C. Kennedy
Department of Dermatology, University Hospitals Bristol Foundation Trust, Bristol, UK
1 shared publicationD M Tole
1 shared publication
Latest Publications
- Open Access
- 3 January 2020
- Published by Springer Nature in Eye
- Vol. 34 (10) , 1825-1834
Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration
Objectives: This report aims to provide clear recommendations and practical guidance from a panel of UK retinal experts on an aflibercept treat-and-extend (T&E) pathway that can be implemented in clinical practice. These recommendations may help service providers across the NHS intending to implement a T&E approach, with the aim of effectively addressing the capacity and resource issues putting strain on UK neovascular age-related macular degeneration (nAMD) services while promoting patients’ best interests throughout. Methods: Two structured roundtable meetings of retinal specialists were held in London, UK on 7 December 2018 and 1 March 2019. These meetings were organised and funded by Bayer. Results: The panel provided recommendations for an aflibercept T&E pathway and developed specific criteria based on visual acuity, retinal morphology and optical coherence tomography imaging to guide reduction, maintenance and extension of injection intervals. They also discussed the extension of treatment intervals by 2- or 4-week adjustments to a maximum treatment interval of 16 weeks, the management of retinal fluid and the stopping of treatment. Conclusions: The long-term benefits of implementing a T&E pathway may include superior visual outcomes compared with a pro re nata (PRN; as needed) protocol, and a lower treatment burden compared with a fixed protocol, which is likely to improve service capacity. Furthermore, the predictable nature of a T&E approach compared with a PRN service may aid capacity planning for the future nAMD treatment demand.
- 3 January 2020
- Published by Springer Nature in Eye
- Vol. 34 (10) , 1825-1834
Open AccessRecommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration
Objectives: This report aims to provide clear recommendations and practical guidance from a panel of UK retinal experts on an aflibercept treat-and-extend (T&E) pathway that can be implemented in clinical practice. These recommendations may help service providers across the NHS intending to implement a T&E approach, with the aim of effectively addressing the capacity and resource issues putting strain on UK neovascular age-related macular degeneration (nAMD) services while promoting patients’ best interests throughout. Methods: Two structured roundtable meetings of retinal specialists were held in London, UK on 7 December 2018 and 1 March 2019. These meetings were organised and funded by Bayer. Results: The panel provided recommendations for an aflibercept T&E pathway and developed specific criteria based on visual acuity, retinal morphology and optical coherence tomography imaging to guide reduction, maintenance and extension of injection intervals. They also discussed the extension of treatment intervals by 2- or 4-week adjustments to a maximum treatment interval of 16 weeks, the management of retinal fluid and the stopping of treatment. Conclusions: The long-term benefits of implementing a T&E pathway may include superior visual outcomes compared with a pro re nata (PRN; as needed) protocol, and a lower treatment burden compared with a fixed protocol, which is likely to improve service capacity. Furthermore, the predictable nature of a T&E approach compared with a PRN service may aid capacity planning for the future nAMD treatment demand.
- Open Access
- 1 April 2011
- Published by Medknow in Saudi Journal of Ophthalmology
- Vol. 25 (2) , 123-129
The management of diabetic macular oedema
Diabetic macular oedema (DMO) is a significant cause of visual loss in the working population. Focal/grid photocoagulation remains an effective treatment for DMO and the benchmark to which clinicians compare other newer treatment modalities. There are, however, patients who do not respond adequately or who are refractory to laser photocoagulation. This has led to the development of newer treatments such as the intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors as well as intravitreal corticosteroid releasing delivery systems. Cataract formation and raised intraocular pressure remain the major disadvantages of corticosteroid use. There is mounting evidence that intravitreal VEGF inhibitors with or without combined laser photocoagulation will become the gold standard treatment for DMO.
- 1 April 2011
- Published by Medknow in Saudi Journal of Ophthalmology
- Vol. 25 (2) , 123-129
Open AccessThe management of diabetic macular oedema
Diabetic macular oedema (DMO) is a significant cause of visual loss in the working population. Focal/grid photocoagulation remains an effective treatment for DMO and the benchmark to which clinicians compare other newer treatment modalities. There are, however, patients who do not respond adequately or who are refractory to laser photocoagulation. This has led to the development of newer treatments such as the intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors as well as intravitreal corticosteroid releasing delivery systems. Cataract formation and raised intraocular pressure remain the major disadvantages of corticosteroid use. There is mounting evidence that intravitreal VEGF inhibitors with or without combined laser photocoagulation will become the gold standard treatment for DMO.
- 16 April 2010
- Published by Taylor & Francis in Orbit
- Vol. 29 (2) , 83-87
The Use of Imiquimod in the Treatment of Periocular Tumours
Purpose: To review our experience with 5% topical Imiquimod in the treatment of periocular tumours. Methods: Imiquimod, an imidazoquinoline, is an immune response modifier which has been shown to have potent anti-viral and anti-tumour activity. We present a retrospective case series of 5 patients who received topical Imiquimod for various eyelid tumours. Two patients were diagnosed with basal cell carcinoma of the eyelid, one patient with actinic keratosis, one with intraepidermal squamous cell carcinoma (Bowen’s disease) and one patient had concomitant squamous cell carcinoma and intraepidermal squamous cell carcinoma. Results: All 5 patients, with various eyelid neoplastic/pre-neoplastic pathology, responded well with clinical resolution, to treatment with topical Imiquimod. There were few adverse reactions to periocular use of 5% Imiquimod, with only 1 patient developing a chemical conjunctivitis which resolved on dose reduction. Conclusions: There is limited experience and published literature on the use of topical 5% Imiquimod in the treatment of periocular tumours. In our experience, it is a safe and effective treatment for periocular lesions, including actinic keratosis, intraepidermal squamous cell carcinoma, basal cell carcinoma and squamous cell carcinoma. To our knowledge, this is the first published description of the successful use of 5% Imiquimod in treating moderately differentiated squamous cell carcinoma of the eyelid.
- 16 April 2010
- Published by Taylor & Francis in Orbit
- Vol. 29 (2) , 83-87
The Use of Imiquimod in the Treatment of Periocular Tumours
Purpose: To review our experience with 5% topical Imiquimod in the treatment of periocular tumours. Methods: Imiquimod, an imidazoquinoline, is an immune response modifier which has been shown to have potent anti-viral and anti-tumour activity. We present a retrospective case series of 5 patients who received topical Imiquimod for various eyelid tumours. Two patients were diagnosed with basal cell carcinoma of the eyelid, one patient with actinic keratosis, one with intraepidermal squamous cell carcinoma (Bowen’s disease) and one patient had concomitant squamous cell carcinoma and intraepidermal squamous cell carcinoma. Results: All 5 patients, with various eyelid neoplastic/pre-neoplastic pathology, responded well with clinical resolution, to treatment with topical Imiquimod. There were few adverse reactions to periocular use of 5% Imiquimod, with only 1 patient developing a chemical conjunctivitis which resolved on dose reduction. Conclusions: There is limited experience and published literature on the use of topical 5% Imiquimod in the treatment of periocular tumours. In our experience, it is a safe and effective treatment for periocular lesions, including actinic keratosis, intraepidermal squamous cell carcinoma, basal cell carcinoma and squamous cell carcinoma. To our knowledge, this is the first published description of the successful use of 5% Imiquimod in treating moderately differentiated squamous cell carcinoma of the eyelid.
- 1 December 2009
- Published by Elsevier in Ophthalmology
- Vol. 116 (12) , 2369-2372
Long-term Topical Steroid Treatment after Penetrating Keratoplasty in Patients with Pseudophakic Bullous Keratopathy
- 1 December 2009
- Published by Elsevier in Ophthalmology
- Vol. 116 (12) , 2369-2372
Long-term Topical Steroid Treatment after Penetrating Keratoplasty in Patients with Pseudophakic Bullous Keratopathy
- 25 March 2009
- Published by BMJ in British Journal of Ophthalmology
- Vol. 93 (4) , 421-422
The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement
A 37-year-old gentleman presented to our clinic with a 3-month history of sore red eyes, treated with topical chloramphenicol for presumed bacterial conjunctivitis. During the preceding 3 months, he reported mouth and penile ulcers, dysphagia, hoarseness and blistering of plantar aspect of his right foot. Examination revealed …
- 25 March 2009
- Published by BMJ in British Journal of Ophthalmology
- Vol. 93 (4) , 421-422
The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement
A 37-year-old gentleman presented to our clinic with a 3-month history of sore red eyes, treated with topical chloramphenicol for presumed bacterial conjunctivitis. During the preceding 3 months, he reported mouth and penile ulcers, dysphagia, hoarseness and blistering of plantar aspect of his right foot. Examination revealed …